James Hoffman

    James M. Hoffman, PharmD

    Associate Member, St. Jude Faculty
    Medication Outcomes & Safety Officer
    Director, Medication-Use Safety Residency Program

    Departments

    Pharmaceutical Sciences

    Contact Information

    James Hoffman, PharmD
    Pharmaceutical Sciences
    MS 150, Room I5103A
    St. Jude Children's Research Hospital
    262 Danny Thomas Place
    Memphis, TN 38105-3678
    Email: james.hoffman@stjude.org
    Phone: (901) 595-2767
    FAX: (901) 595-3111

    Education

    BS - Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania
    PharmD - Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania
    MS - School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin


    Honors & Awards


    Research Interests


    Selected Publications

    Burlison JD, Scott SD, Browne EK, Thompson SG, Hoffman JM. The Second Victim Experience and Support Tool: Validation of an Organizational Resource for Assessing Second Victim Effects and the Quality of Support Resources. J Patient Saf Aug. 26, 2014.

    Call RJ, Burlison JD, Robertson JJ, Scott JR, Baker DK, Rossi MG, Howard SC, Hoffman JM. Adverse drug event detection in pediatric oncology and hematology patients: using medication triggers to identify patient harm in a specialized pediatric patient population. J Pediatr April 24, 2014.

    Hoffman JM, Haidar CE, Wilkinson MR, Crews KR, Baker DK, Kornegay NM, Yang W, Pui CH, Reiss UM, Gaur AH, Howard SC, Evans WE, Broeckel U, Relling MV. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet 166(1):45-55, 2014.

    Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, Hicks JK, Wilkinson MR, Haas DW, Kroetz DL. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for HLA-B genotype and abacavir dosing: 2014 update. Clin Pharmacol Ther Feb 21, 2014.

    Petschonek S, Burlison J, Cross C, Martin K, Laver J, Landis RS, Hoffman JM. Development of the Just Culture Assessment Tool: measuring the perceptions of health-care professionals in hospitals. J Patient Saf 9(4):190-7, 2013.

    Bell GC, Crews KR, Wilkinson MR, Haidar CE, Hicks JK, Baker DK, Kornegay NM, Yang W, Cross SJ, Howard SC, Freimuth RR, Evans WE, Broeckel U, Relling MV, Hoffman JM. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc August 26, 2013.

    McBride A, Holle LM, Westendorf C, Sidebottom M, Griffith N, Muller RJ, Hoffman JM. National survey on the effect of oncology drug shortages on cancer care. Am J Health Syst Pharm 70(7):609-17, 2013.

    Hoffman JM, Li E, Doloresco F, Matusiak L, Hunkler RJ, Shah ND, Vermeulen LC, Schumock GT. Projecting future drug expenditures in U.S. nonfederal hospitals and clinics—2013. Am J Health Syst Pharm 70(6):525-539, 2013.

    Hoffman JM, Frediani J, Herr M, Flynn PM, Adderson EE. The safety of cefepime and ceftazidime in pediatric oncology patients.Pediatr Blood Cancer 60(5):806-809, 2013.

    Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, Lorier R, Stoddard A, Yang W, Smith C,Fernandez CA, Cross SJ, Haidar C, Baker DK, Howard SC, Evans WE, Broeckel U, Relling MV. A clinician driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharm Ther 92(5):563-566, 2012.

    Hoffman JM, Li E, Doloresco F, Matusiak L, Hunkler RJ, Shah ND, Vermeulen LC, Schumock GT. Projecting future drug expenditures--2012. Am J Health Syst Phar 69(5):405-421, 2012.

    Christensen AM, Pauley JL, Molinelli AR, Panetta JC, Ward DA, Stewart CF, Hoffman JM, Howard SC, Pui CH, Pappo AS, Relling MV, Crews KR. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer 118(17):4321-4330, 2012.

    Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH, Markus R, Matulonis UA, Reinke D, Li EC, DeMartino J, Larsen JK, Hoffman JM. NCCN Biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw 9(Supppl 4):S1-S22, 2011.

    Shenep LE, Shenep MA, Cheatham W, Hoffman JM, Hale A, Williams BF, Perkins R, Hewitt CB, Hayden RT, Shenep JL. Efficacy of intravascular catheter lock solutions containing preservatives in the prevention of microbial colonization. J Hosp Infect 79(4):317-322, 2011.

    Doloresco F, Vermeulen LC, Shah ND, Matusiak L, Hunkler RJ, Schumock GT. Hoffman JM. Projecting future drug expenditures-2011. Am J Health Syst Pharm 68:921-32, 2011.

    Hoffman JM, Baker DK, Howard SC, Laver JH, Shenep JL. Safe and Successful Implementation of CPOE for Chemotherapy at a Children’s Cancer Center. J Natl Compr Canc Netw 9:S36-S50, 2011.

    Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, Mullins R, Relling MV, Hoffman JM. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 68:143-50, 2011.

    Johnson PE, Dahlman G, Garg R, Gottlieb S, Hoffman JM, Howell P, Jahanzeb M, Johnson S, Mackler E. Rubino M, Sarokhan B, Stewart FM, Tyler T, Vose JM, Weinstein S, Li EC, DeMartino J. NCCN oncology risk evaluation and mitigation strategies white paper: recommendations for stakeholders. J Natl Compr Canc Netw 8:S7-S27 Suppl. 7, 2010.

    Stubbings JA, Joshi R, Hoffman JM. Risk evaluation and mitigation strategies (REMS): Challenges and opportunities for pharmacists. Am J Health Syst Pharm 67:1547-1454, 2010.

    Adderson EE, Flynn PM, Hoffman JM. Efficacy and safety of cefepime in pediatric patients: a systematic review and meta-analysis. J Pediatr 157(3):490-495, 495.e1, 2010.

    Hoffman JM, Doloresco F, Vermeulen LC, Shah ND, Matusiak L, Hunkler RJ, Schumock GT. Projecting future drug expenditures-2010. Am J Health Syst Pharm 67:919-928, 2010.

    Gaur AH, Bagga B, Barman S, Hayden R, Lamptey A, Hoffman JM, Bhojwani D, Flynn PM, Tuomanen E, Webby R. Intravenous Zanamivir for Oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 362(1):88-89, 2010. Epub 2009 Dec 23.

    Hoffman JM, Shah ND, Vermeulen LC, Doloresco F, Martin PK, Blake S, Matusiak, L, Hunkler RJ, Schumock GT.  Projecting future drug expenditures – 2009. Am J Health-Syst Pharm 66:237-257, 2009.

    Perez A, Doloresco F, Hoffman JM, Meek PD, Touchette DR, Vermeulen LC, Schumock GT; American College of Clinical Pharmacy. Economic evaluations of clinical pharmacy services: 2001-2005. Pharmacotherapy 29(1):128, 2009.

    Baker DK, Hoffman JM, Hale GA, Spunt SL, Sanderlin D, Rodman JH, Shenep JL.  Analysis of patient safety: converting complex pediatric chemotherapy ordering processes from paper to electronic systems. Advances in Patient Safety: New Directions and Alternative Approaches. Volumes 2, AHRQ Publication Nos. 08-0034 (1-4). July 2008. Agency for Healthcare Research and Quality, Rockville, Available at: http://www.ahrq.gov/downloads/pub/advances2/vol2/Advances-Baker_107.pdf.

    Rubino M, Hoffman JM, Koesterer LJ, Swendrzynski RG. ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems. Developed by an ASHP Expert Panel on Medication Cost Management. Am J Health-Syst Pharm 65:1368-1384, 2008.

    Hoffman JM, Shah ND, Vermeulen LC, Doloresco F, Schumock GT, Hunkler RJ, Hontz KM, Grim P. Projecting future drug expenditures – 2008. Am J Health-Syst Pharm 65:234-253, 2008.

    Relling MV, Hoffman JM. Should pharmacogenomic studies be required for new drug approval? Clin Pharmacol Ther 81:425-428, 2007.

    Hoffman JM, Shah ND, Vermeulen LC, Schumock GT, Hunkler RJ, Hontz KM, Grim P. Projecting future drug expenditures – 2007. Am J Health-Syst Pharm 64:298-314, 2007.

    Hoffman JM, Shah ND, Vermeulen LC, Schumock GT, Hunkler RJ, Hontz KM, Grim P. Projecting future drug expenditures – 2006. Am J Health-Syst Pharm 63:123-138, 2006.

     

    Last update: September 2014